MEI Pharma Inc. Daily Stock Analysis

Daily Stock Analysis, MEIP, MEI Pharma Inc, priceseries

MEI Pharma Inc. Daily Stock Analysis
Stock Information
Open
1.99
Close
2.01
High
2.04
Low
1.92
Previous Close
1.97
Daily Price Gain
0.04
YTD High
2.80
YTD High Date
Jan 4, 2022
YTD Low
1.68
YTD Low Date
Feb 3, 2022
YTD Price Change
-0.73
YTD Gain
-26.64%
52 Week High
3.94
52 Week High Date
Mar 15, 2021
52 Week Low
1.68
52 Week Low Date
Feb 3, 2022
52 Week Price Change
-1.61
52 Week Gain
-44.48%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 6. 2017
1.55
Feb 22. 2017
1.70
11 Trading Days
9.92%
Link
LONG
May 24. 2017
1.67
Jun 6. 2017
1.99
8 Trading Days
18.87%
Link
LONG
May 14. 2018
2.53
May 23. 2018
2.94
7 Trading Days
16.30%
Link
LONG
May 30. 2018
3.30
Jun 15. 2018
4.16
12 Trading Days
25.99%
Link
LONG
Aug 20. 2018
3.79
Aug 31. 2018
4.19
9 Trading Days
10.57%
Link
LONG
Sep 4. 2019
1.70
Sep 20. 2019
1.92
12 Trading Days
12.86%
Link
LONG
Dec 23. 2019
2.00
Jan 7. 2020
2.24
9 Trading Days
12.04%
Link
LONG
Mar 23. 2020
1.18
Mar 27. 2020
1.34
4 Trading Days
13.66%
Link
LONG
Apr 3. 2020
1.46
Jun 11. 2020
3.59
47 Trading Days
145.94%
Link
LONG
Sep 9. 2020
2.68
Sep 23. 2020
3.15
10 Trading Days
17.66%
Link
LONG
Dec 21. 2020
2.92
Dec 24. 2020
3.09
3 Trading Days
5.99%
Link
LONG
Jan 28. 2021
3.16
Feb 18. 2021
3.91
14 Trading Days
23.88%
Link
LONG
Nov 1. 2021
2.85
Nov 10. 2021
3.02
7 Trading Days
6.02%
Link
Company Information
Stock Symbol
MEIP
Exchange
NasdaqCM
Company URL
http://www.meipharma.com
Company Phone
858-792-6300
CEO
Daniel P. Gold
Headquarters
California
Business Address
3611 VALLEY CENTER DRIVE, SUITE 500, SAN DIEGO, CA 92130
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Other
CIK
0001262104
About

MEI Pharma, Inc. is an oncology company, which engages in clinical development of novel small molecules for the treatment of cancer. Its portfolio of drug candidates includes Pracinostat, an oral inhibitor that is poised to enter a phase study for the treatment of elderly patients with newly diagnosed acute myeloid leukemia (AML). The company was founded on December 1, 2000 and is headquartered in San Diego, CA.

Description

MEI Pharma, Inc., an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading